Halted trial tests new hope for blood disorder
NCT ID NCT05148234
Summary
This early-stage study tested a new drug, BMS-986253, for adults with myelodysplastic syndromes (MDS), a serious bone marrow disorder. The goal was to see if the drug was safe and could help control the disease, either alone or combined with standard medications. The trial was terminated very early, enrolling only 2 participants, so no conclusions about effectiveness could be made.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.